{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:54:10Z","timestamp":1788047650381,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008276","name":"University of Florida College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.vph.2021.106948","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T21:27:24Z","timestamp":1637962044000},"page":"106948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Differential effects of cyclooxygenase-2 (COX-2) inhibitors on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells"],"prefix":"10.1016","volume":"142","author":[{"given":"Michael J.","family":"Haas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Warda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Bikkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Angelica","family":"Landicho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrina","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshag D.","family":"Mooradian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2021.106948_bb0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/pr.56.3.3","article-title":"Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition","volume":"56","author":"Simmons","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.vph.2021.106948_bb0010","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gut.47.3.320","article-title":"COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors","volume":"47","author":"Whittle","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.vph.2021.106948_bb0015","series-title":"FDA public health advisory: safety of Vioxx. September 30","author":"Food and Drug Administration","year":"2004"},{"key":"10.1016\/j.vph.2021.106948_bb0020","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"38","key":"10.1016\/j.vph.2021.106948_bb0025","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1093\/eurheartj\/ehx508","volume":"2017","author":"Ruschitzka","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2021.106948_bb0030","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2021.106948_bb0035","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: celecoxib long-term arthritis safety study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2021.106948_bb0040","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","article-title":"Celecoxib for the prevention of colorectal adenomatous polyps","volume":"355","author":"Arber","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2021.106948_bb0045","first-page":"306","article-title":"COX-2 derived prostacyclin confers atheroprotection on female mice","volume":"2004","author":"Egan","year":"1954","journal-title":"Science"},{"key":"10.1016\/j.vph.2021.106948_bb0050","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/CIRCULATIONAHA.106.682054","article-title":"Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome","volume":"116","author":"Myoishi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2021.106948_bb0055","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.108.183749","article-title":"Oxidized low density lipoproteins trigger endoplasmic reticulum stress in vascular cells: prevention by oxygen-regulated protein expression","volume":"104","author":"Sanson","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2021.106948_bb0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40256-016-0199-7","article-title":"Therapeutic targeting of cellular stress to prevent cardiovascular disease. A review of the evidence","volume":"17","author":"Mooradian","year":"2017","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.vph.2021.106948_bb0065","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkl515","article-title":"Real-time detection and continuous monitoring of ER stress in vitro and in vivo by ES-TRAP: evidence for systemic, transient ER stress during endotoxemia","volume":"34","author":"Hiramatsu","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.vph.2021.106948_bb0070","first-page":"5","article-title":"The bicinchoninic acid (BCA) assay for protein quantitation","volume":"32","author":"Walker","year":"1994","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.vph.2021.106948_bb0075","first-page":"6","article-title":"Analysis of cell viability by the MTT assay","volume":"2018","author":"Kumar","year":"2018","journal-title":"Cold Spring Harb Protoc"},{"key":"10.1016\/j.vph.2021.106948_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173119","article-title":"High-throughput analysis identifying drugs that reduce oxidative and ER stress in human coronary artery endothelial cells","volume":"879","author":"Haas","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.vph.2021.106948_bb0085","first-page":"2699","article-title":"Combining CAL-101 with celecoxib enhances apoptosis of EBV-transformed B-cells through MAPK-induced ER stress","volume":"35","author":"Park","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.vph.2021.106948_bb0090","first-page":"4526","article-title":"Sequential treatment with celecoxib and bortezomib enhances the ER stress-mediated autophagy-associated cell death of colon cancer cells","volume":"16","author":"Park","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.vph.2021.106948_bb0095","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5483\/BMBRep.2017.50.3.197","article-title":"Celecoxib-mediated activation of endoplasmic reticulum stress induces de novo ceramide biosynthesis and apoptosis in hepatoma HepG2 cells mobilization","volume":"50","author":"Maeng","year":"2017","journal-title":"BMB Rep."},{"key":"10.1016\/j.vph.2021.106948_bb0100","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00280-016-2996-8","article-title":"Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo","volume":"77","author":"Xu","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.vph.2021.106948_bb0105","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cas.13106","article-title":"Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt\/\u03b2-catenin signaling pathway","volume":"108","author":"Egashira","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.vph.2021.106948_bb0110","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3390\/cancers11070931","article-title":"Synergy between auranofin and celecoxib against colon cancer in vitro and in vivo through a novel redox-mediated mechanism","volume":"11","author":"Han","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.vph.2021.106948_bb0115","first-page":"613","article-title":"Cyclooxygenase-2 expression is induced by celecoxib treatment in lung cancer cells and is transferred to neighbor cells via exosomes","volume":"52","author":"Kim","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.vph.2021.106948_bb0120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cmdc.201800685","article-title":"Carboranyl analogues of celecoxib with potent cytostatic activity against human melanoma and colon cancer cell lines","volume":"14","author":"Buzharevski","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.vph.2021.106948_bb0125","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/sj.onc.1210894","article-title":"Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153\/CHOP","volume":"27","author":"He","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.vph.2021.106948_bb0130","doi-asserted-by":"crossref","first-page":"41310","DOI":"10.1074\/jbc.M110.153775","article-title":"ERK\/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1","volume":"285","author":"Oh","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2021.106948_bb0135","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bcp.2007.08.029","article-title":"Celecoxib transiently inhibits cellular protein synthesis","volume":"75","author":"Pyrko","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.vph.2021.106948_bb0140","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1211\/0022357021387","article-title":"Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects","volume":"55","author":"Ahuja","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.vph.2021.106948_bb0145","first-page":"332","article-title":"COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter","volume":"7","author":"Davies","year":"2004","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.vph.2021.106948_bb0150","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ab.2004.08.019","article-title":"Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic\/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer","volume":"334","author":"Murphey","year":"2004","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.vph.2021.106948_bb0155","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1538-7836.2007.02782.x","article-title":"Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers","volume":"5","author":"Graff","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2021.106948_bb0160","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tiv.2015.12.003","article-title":"Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria","volume":"32","author":"Syed","year":"2016","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.vph.2021.106948_bb0165","first-page":"26","year":"1998","journal-title":"Searle Pfizer"},{"key":"10.1016\/j.vph.2021.106948_bb0170","unstructured":"Mobic and Mobic Oral Suspension product insert, Boehringer Mannheim."},{"key":"10.1016\/j.vph.2021.106948_bb0175","unstructured":"Vioxx product insert, Merck."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189121001208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189121001208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:21:31Z","timestamp":1761528091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189121001208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":35,"alternative-id":["S1537189121001208"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2021.106948","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential effects of cyclooxygenase-2 (COX-2) inhibitors on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2021.106948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106948"}}